Triple therapy safety
NEW YORK, July 18 (Praxis Press) Multidrug antiretroviral therapy has decreased the morbidity and mortality associated with human immunodeficiency virus (HIV) infection, but the long-term effects and safety of this treatment are unknown. Gulick and colleagues studied the durability and toxicity associated with combined indinavir, zidovudine and lamivudine therapy in HIV-infected patients (see paper). Almost 65% of patients continued therapy for three years. Serum viral loads remained suppressed
The Scientist Staff
Jul 20, 2000
NEW YORK, July 18 (
Interested in reading more?
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?